CAS Number153504-70-2
Synonymscis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride hemihydrate; cevimeline hydrochloride; CeviMeline hydrochloride heMihydrates; Cevimeline hydrochloride hemihydrate; (2R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride hydrate (2:2:1); (±)-cis-2-methylspiro[1,2-oxathiolane-5,3'-quinclidine] monohydrochloride; (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride; (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]monohydrochloride hemihydrate; CevimelineHCl; Cevimeline (hydrochloride hemihydrate)
Molecular FormulaC20H35ClN2O2S2
Molecular Weight199.31 (anhydrous free base basis)
Density1.19g/cm3
Boiling Point308.5ºC at 760mmHg
Appearancesolid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 153504-70-2 |
| Catalog No. | 2A-3183293 |
| Chinese Name | 盐酸西维美林 |
| Synonyms | cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride hemihydrate; cevimeline hydrochloride; CeviMeline hydrochloride heMihydrates; Cevimeline hydrochloride hemihydrate; (2R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride hydrate (2:2:1); (±)-cis-2-methylspiro[1,2-oxathiolane-5,3'-quinclidine] monohydrochloride; (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride; (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]monohydrochloride hemihydrate; CevimelineHCl; Cevimeline (hydrochloride hemihydrate) |
| Molecular Formula | C20H35ClN2O2S2 |
| Molecular Weight | 199.31 (anhydrous free base basis) |
| Density | 1.19g/cm3 |
| Boiling Point | 308.5ºC at 760mmHg |
| Appearance | solid |
| Storage Condition | -20°C |
| Application | Cevimeline hydrochloride hemihydrate is a muscarinic receptor agonist. |
| PubChem ID | 329825084 |
| SMILES | CC1OC2(CS1)CN1CCC2CC1.CC1OC2(CS1)CN1CCC2CC1.Cl.Cl.O |
| InChI | InChI=1S/2C10H17NOS.2ClH.H2O/c2*1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;;/h2*8-9H,2-7H2,1H3;2*1H;1H2/t2*8-,10-;;;/m11.../s1 |
| InChI Key | ZSTLCHCDLIUXJE-GMLJRNIPSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Bioactivity | Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value:Target: mAChRThe general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI-2011 was also evaluated with rat and dog liver microsomes. After oral administration, plasma concns. of SNI-2011 reached to Cmax within 1 h in both species, suggesting that SNI-2011 was quickly absorbed, and then decreased with a t1/2 of 0.4-1.1 h. The bioavailability was 50% and 30% in rats and dogs, resp. Major metabolites in plasma were both S- and N-oxidized metabolites in rats and only N-oxidized metabolite in dogs, indicating that a large species difference was obsd. in the metab. of SNI-2011. Sex difference was also obsd. in the pharmacokinetics of SNI-2011 in rats, but not in dogs. In the in vitro study, chem. inhibition and pH-dependent studies revealed that the sulfoxidn. and N-oxidn. of SNI-2011 were mediated by cytochrome P 450 (CYP) and flavin-contg. monooxygenase (FMO), resp., in both species. In addn., CYP2D and CYP3A were mainly responsible for the sulfoxidn. in rat liver microsomes. Related Catalog Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Neurological Disease References [1]. Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, Masunaga H, Yasuda H, Miyata N. (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions [2]. Omori Y, Asari T, Maruyama K, Kusama H, Kojima M, Shibata N. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung. 2003;53(5):342-50. [3]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of radiolabeled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: Comprehensive understanding of absorption, metabolism and excretion using radi [4]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs.Arzneimittel-Forschung (2003), 53(1), 26-33. [5]. Arisawa, Hirohiko; Fukui, Kenji; Imai, Eiichi; et al.General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren's syndrome. Arzneimittel-Forschung (2002), 52(4), 225-232. Chemical & Physical Properties Density 1.19g/cm3 Boiling Point 308.5ºC at 760mmHg Molecular Formula C20H35ClN2O2S2 Molecular Weight 435.09 Flash Point 140.4ºC PSA 84.77000 LogP 4.53590 Vapour Pressure 0.000676mmHg at 25°C InChIKey ZSTLCHCDLIUXJE-GMLJRNIPSA-N SMILES CC1OC2(CS1)CN1CCC2CC1.CC1OC2(CS1)CN1CCC2CC1.Cl.Cl.O Storage condition -20°C |
| Use of | Properties Name Cevimelinehydrochloride Synonym More Synonyms Cevimeline hydrochloride hemihydrate Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Neurological Disease References [1]. Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, Masunaga H, Yasuda H, Miyata N. (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions [2]. Omori Y, Asari T, Maruyama K, Kusama H, Kojima M, Shibata N. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung. 2003;53(5):342-50. [3]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of radiolabeled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: Comprehensive understanding of absorption, metabolism and excretion using radi [4]. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; et al.Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs.Arzneimittel-Forschung (2003), 53(1), 26-33. [5]. Arisawa, Hirohiko; Fukui, Kenji; Imai, Eiichi; et al.General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjogren's syndrome. Arzneimittel-Forschung (2002), 52(4), 225-232. Chemical & Physical Properties PSA 84.77000 LogP 4.53590 InChIKey ZSTLCHCDLIUXJE-GMLJRNIPSA-N |
| Transport Info | Product name: cevimeline hydrochloride hemihydrate |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 3-(N-Phenyl-N-methyl)aminoacrolein | 14189-82-3 | 2A-3183286 |
| Isoprophalin fumarate | 2A-3183288 | 2A-3183288 |
| 1 1-DIMETHYLBIGUANIDE HYDROCHLORIDE | 15537-72-1 | 2A-3183290 |
| Cordycepin powder | 2A-3183291 | 2A-3183291 |
| Thymopentin acetate | 2A-3183292 | 2A-3183292 |
| (3S)-3-(2-Thienylthio)butanoic acid compd. with (alphaR)-alpha-methylbenzenemethanamine | 1197375-23-7 | 2A-3183294 |
| PropylsulfaMide | 147962-41-2 | 2A-3183301 |
| SulfaMide, N-propyl-,(potassiuM salt)(1:1) | 1393813-41-6 | 2A-3183302 |
| Benzamide,N-[2-amino-4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-4-methoxy- | 74149-74-9 | 2A-3183303 |
| 4-chloro-4'-(diphenylaMino)biphenyl | 880800-25-9 | 2A-3183306 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS